Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial

Many Canadians received a novel AS03-adjuvanted vaccine during the 2009 influenza A/H1N1 pandemic. Longer term implications of adjuvant use were unclear: would anti-H1N1 immune responses persist at high levels and, if so, could that result in increased or unusual adverse effects upon re-exposure to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scheifele, David W., Dionne, Marc, Ward, Brian J., Cooper, Curtis, Vanderkooi, Otto G., Li, Yan, Halperin, Scott A., Influenza Research Network, PHAC/CIHR
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3667929/
https://ncbi.nlm.nih.gov/pubmed/23570051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.22619
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars